Q-omics provides the consensus-scored CYP51A1P3 profile across patient tissues and cancer cell-line models. CYP51A1P3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CYP51A1P3 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CYP51A1P3 RNA expression shows 6,896 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, HNSC, and UVM as cancer lineages where CYP51A1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP51A1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP51A1P3 survival associations across molecular data types. CYP51A1P3 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP51A1P3 RNA expression–survival associations across cancer types. High CYP51A1P3 expression shows unfavorable associations in COAD, KICH, MESO, ACC and KIRC, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CYP51A1P3 RNA expression.
This table summarizes CYP51A1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP51A1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP51A1P3 shows lower tumor expression in HNSC, THCA, LUSC, KICH, KIRC and LUAD. The HNSC box plot shows higher CYP51A1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.078, t-test p < 0.001).
This table shows molecular features associated with CYP51A1P3 in patient tissues and cancer cell lines. In patient samples, CYP51A1P3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
